171 related articles for article (PubMed ID: 9700724)
1. Tumor-specific IgE-mediated inhibition of human colorectal carcinoma xenograft growth.
Kershaw MH; Darcy PK; Trapani JA; MacGregor D; Smyth MJ
Oncol Res; 1998; 10(3):133-42. PubMed ID: 9700724
[TBL] [Abstract][Full Text] [Related]
2. Chimeric (mouse/human) anti-colon cancer antibody c30.6 inhibits the growth of human colorectal cancer xenografts in scid/scid mice.
Mount PF; Sutton VR; Li W; Burgess J; McKEnzie IF; Pietersz GA; Trapani JA
Cancer Res; 1994 Dec; 54(23):6160-6. PubMed ID: 7954462
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effects of a bispecific antibody targeting CA19-9 antigen and CD16.
Garcia de Palazzo I; Holmes M; Gercel-Taylor C; Weiner LM
Cancer Res; 1992 Oct; 52(20):5713-9. PubMed ID: 1394194
[TBL] [Abstract][Full Text] [Related]
4. Specific targeting and killing activities of anti-P-glycoprotein monoclonal antibody MRK16 directed against intrinsically multidrug-resistant human colorectal carcinoma cell lines in the nude mouse model.
Iwahashi T; Okochi E; Ariyoshi K; Watabe H; Amann E; Mori S; Tsuruo T; Ono K
Cancer Res; 1993 Nov; 53(22):5475-82. PubMed ID: 8106147
[TBL] [Abstract][Full Text] [Related]
5. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
[TBL] [Abstract][Full Text] [Related]
6. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
[TBL] [Abstract][Full Text] [Related]
7. Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells.
Karagiannis SN; Wang Q; East N; Burke F; Riffard S; Bracher MG; Thompson RG; Durham SR; Schwartz LB; Balkwill FR; Gould HJ
Eur J Immunol; 2003 Apr; 33(4):1030-40. PubMed ID: 12672069
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibody homodimers: enhanced antitumor activity in nude mice.
Wolff EA; Schreiber GJ; Cosand WL; Raff HV
Cancer Res; 1993 Jun; 53(11):2560-5. PubMed ID: 8495420
[TBL] [Abstract][Full Text] [Related]
9. Antitumor IgE adjuvanticity: key role of Fc epsilon RI.
Nigro EA; Brini AT; Soprana E; Ambrosi A; Dombrowicz D; Siccardi AG; Vangelista L
J Immunol; 2009 Oct; 183(7):4530-6. PubMed ID: 19748979
[TBL] [Abstract][Full Text] [Related]
10. Detection and characterization of monoclonal antibodies specific to IgE receptors on human lymphocytes by flow cytometry.
Rector E; Nakajima T; Rocha C; Duncan D; Lestourgeon D; Mitchell RS; Fischer J; Sehon AH; Delespesse G
Immunology; 1985 Jul; 55(3):481-8. PubMed ID: 3160655
[TBL] [Abstract][Full Text] [Related]
11. Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors.
Gillies SD; Lan Y; Lo KM; Super M; Wesolowski J
Cancer Res; 1999 May; 59(9):2159-66. PubMed ID: 10232603
[TBL] [Abstract][Full Text] [Related]
12. Novel IgE peptide-based vaccine prevents the increase of IgE and down-regulates elevated IgE in rodents.
Peng Z; Liu Q; Wang Q; Rector E; Ma Y; Warrington R
Clin Exp Allergy; 2007 Jul; 37(7):1040-8. PubMed ID: 17581197
[TBL] [Abstract][Full Text] [Related]
13. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
Wu Y; Zhong Z; Huber J; Bassi R; Finnerty B; Corcoran E; Li H; Navarro E; Balderes P; Jimenez X; Koo H; Mangalampalli VR; Ludwig DL; Tonra JR; Hicklin DJ
Clin Cancer Res; 2006 Nov; 12(21):6573-84. PubMed ID: 17085673
[TBL] [Abstract][Full Text] [Related]
14. [Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model].
Wang YD; Hu Y; Zhang L; Huang J; Sun CY
Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):659-63. PubMed ID: 18399169
[TBL] [Abstract][Full Text] [Related]
15. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy.
Yang XD; Jia XC; Corvalan JR; Wang P; Davis CG; Jakobovits A
Cancer Res; 1999 Mar; 59(6):1236-43. PubMed ID: 10096554
[TBL] [Abstract][Full Text] [Related]
16. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
[TBL] [Abstract][Full Text] [Related]
17. Target-specific activation of mast cells by immunoglobulin E reactive with a renal cell carcinoma-associated antigen.
Luiten RM; Fleuren GJ; Warnaar SO; Litvinov SV
Lab Invest; 1996 Feb; 74(2):467-75. PubMed ID: 8780164
[TBL] [Abstract][Full Text] [Related]
18. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
[TBL] [Abstract][Full Text] [Related]
19. In vivo antitumor effects of monoclonal antibodies with different immunoglobulin classes.
Seto M; Takahashi T; Nakamura S; Matsudaira Y; Nishizuka Y
Cancer Res; 1983 Oct; 43(10):4768-73. PubMed ID: 6192909
[TBL] [Abstract][Full Text] [Related]
20. Effector mechanism in antitumor activity of monoclonal antibodies produced against an ascitic mouse mammary tumor.
Seto M; Takahashi T; Nakamura S; Saito M; Hara T; Nishizuka Y
Cancer Res; 1986 Apr; 46(4 Pt 2):2056-61. PubMed ID: 3004718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
